Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Regions Seek To Bolster Domestic Production Capacity As Weaknesses Exposed
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
You may also be interested in...
Sanofi Seeks Independence For API Unit Despite Stormy Market
The French drugmaker is pushing ahead with a listing of its Euroapi business on the Euronext in the next couple of months, in spite of the turbulence that the Russian invasion of Ukraine has brought to stock markets.
Joined-Up EU Approach Is Key To Continuing COVID-19 Fight
At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.
Canadian Body Calls For Investment In Domestic Production
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.